Factors Affecting Lung Cancer Survival: A Literature Review

Naeima Houssein1*

1Department of Epidemiology, Faculty of Public Health, University of Benghazi, Libya.

Author’s contribution

The sole author designed, analysed, interpreted and prepared the manuscript.

ABSTRACT

Lung cancer is a disease which invades the lung tissue by formation of uncontrolled cell growth, and this may also affect the tissues near the lung. There are a wide range of prognostic factors which determine survival duration of lung cancer patients. Among the most important factors are patient demographics, disease factors and health care related factors. Lung cancer remains one of the leading causes of the overall cancer burden worldwide. The aim of this review is to investigate the existing knowledge and relevant literature on prognostic factors in lung cancer survival. Literature search was carried on OVID databases (1990-2011) that include Ovid MEDLINE in process and EMBASE. In Ovid, truncations were used. Only papers published in English were included. A total of 315 were found and refined, only 43 papers were reviewed. In conclusion, lung cancer survival is influenced by a number of factors that interact to determine the prognosis of patients. Lung cancer survival is not dependent on a single factor of these prognostics, but is affected by the interaction between them.

Keywords: Lung cancer; survival; prognostic factors.
1. INTRODUCTION

Lung cancer is a disease which invades the lung tissue by formation of uncontrolled cell growth, and this may also affect the tissues near the lung (Metastasis). The primary type of lung cancer is histologically divided into two main types, which are small cell lung carcinoma and non-small cell lung carcinoma. The former accounts for 20% of lung cancer cases, and it is divided into two stages, limited and extensive, whereas the latter represents 80% of cases and it is staged into four stages based on the international Tumour Node Metastases (TNM) staging system, which is used for describing the extent of cancer in the body of the patient. Both cancers behave differently in terms of treatment response and prognosis. Non-small cell lung carcinoma (NSCLC) is sometimes treated with surgery, while small cell lung carcinoma (SCLC) usually responds better to Chemotherapy and radiation [1]. Smoking represents the most direct cause of lung cancer and leads to 90% of lung cancer deaths [2]. Nevertheless, there are other causes leading to lung cancer in non-smoking people attributed to genetic factors and air pollutants such as asbestos, radon gas, and passive smoking [3].

Lung cancer remains one of the leading causes of the overall cancer burden worldwide. On average, lung cancer accounts for 12.3% of all new cancer cases [4,5] in their comprehensive study on prognostic factors in lung cancer pointed out that the number of potentially associated factors with lung cancer outcomes is certainly more than one hundred. The aim of is to investigate the existing knowledge and relevant literature on prognostic factors in lung cancer survival.

2. METHODS

Literature search was carried on OVID databases (1990-2011) that include Ovid MEDLINE in process and EMBASE. Further relevant studies were identified by searching the references in the obtained full text papers. Table 1 shows search terms and results of literature search in Ovid, including relevant studies that were published in English. There were 10 searches for each factor affecting survival separately with specific search terms on sex, age, socioeconomic status, performance status, clinical stage, surgery, chemotherapy, radiotherapy, comorbidity and health care. Truncations were used.

<table>
<thead>
<tr>
<th>Search number</th>
<th>Search terms : In title (Duplicate removed)</th>
<th>Limits: English Language and 1990-2011</th>
<th>Relevant results</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>(lung cancer* or lung neoplasm* or lung tumo<em>r</em> or respiratory cancer* or respiratory neoplasm* or respiratory tumo<em>r</em>) and (sex* or gender*) and survival</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>(lung cancer* or lung neoplasm* or lung tumo<em>r</em> or respiratory cancer* or respiratory neoplasm* or respiratory tumo<em>r</em>) and survival and age</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>(lung cancer* or lung neoplasm* or lung tumo<em>r</em> or respiratory cancer* or respiratory neoplasm* or respiratory tumo<em>r</em>) and survival and (depriv* or socioeconomic* or poverty)</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>(lung cancer* or lung neoplasm* or lung tumo<em>r</em> or respiratory cancer* or respiratory neoplasm* or respiratory tumo<em>r</em>) and survival and performance status</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>(lung cancer* or lung neoplasm* or lung tumo<em>r</em> or respiratory cancer* or respiratory neoplasm* or respiratory tumo<em>r</em>) and (clinical stage or tumo*r size ) and survival</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>(lung cancer* or lung neoplasm* or lung tumo<em>r</em> or respiratory cancer* or respiratory neoplasm* or respiratory tumo<em>r</em>) and survival and surgery</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>(lung cancer* or lung neoplasm* or lung tumo<em>r</em> or respiratory cancer* or respiratory neoplasm* or respiratory tumo<em>r</em>) and survival and chemotherapy</td>
<td>152</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>(lung cancer* or lung neoplasm* or lung tumo<em>r</em> or respiratory cancer* or respiratory neoplasm* or respiratory tumo<em>r</em>) and survival and radiothrap*</td>
<td>47</td>
<td></td>
</tr>
</tbody>
</table>
3. LITERATURE REVIEW

3.1 Patient Factors

3.1.1 Sex

The importance of sex as a prognostic factor was highlighted by some researchers. In a retrospective cohort study conducted in Brazil, researchers analysed data of 253 patients of non-small cell lung cancer and observed a 5-year survival rate of 85.5% in females and 46.4% in males [6]. These results were obtained after adjusting for age, smoking habit, haemoglobin, tumour size, tumour-node-metastasis stage, prospective complication and surgery type.

Another cohort study from Taiwan was conducted on 695 patients (315 females and 380 males) who were enrolled in the study between January 2002 and December 2005. The study revealed that the better prognosis was found in females compared to males (685 vs. 493 days) after adjustment for age, disease stage and smoking history [7]. There was substantial evidence of sex being a predictor in lung cancer prognosis.

All these studies reported better survival in women after receiving treatment for lung cancer. However, these studies failed to clarify the reason of difference. It has been suggested in other studies that survival advantage associated with women might be due to different natural history of disease and tumour biology [8]. Another potential cause of difference in survival may be related to difference in treatment response in both sexes [9]. With considerations to reported findings on lung cancer survival and sex, it appears that further studies are needed to adjust for age related differences in death resulting from unrelated cause (life expectancy) which might have confounded the results.

3.1.2 Age

Age is a decisive factor in treatment option and outcome of a lung cancer patient. Older age is shown to be associated with poor prognosis. A prospective study on patients of non-small lung cancer showed that elderly patients survived for an average of 39 months after surgery compared to an average of 49 months by younger patients [10].

Similarly, a retrospective study conducted on 519 patients showed results suggesting poor prognosis for older patients compared to younger patients [11]. This is in contrast to other studies that consider age of patients as not an important prognostic factor in lung cancer survival and treatment.

A prospective study by Takigawa et al. [12] on 185 NSCLC patients found no significant effect of age on survival. Hurria and Kris [13] in their review pointed out that older patients should not be defined by their chronological age, but assessment of their physiological age should be taken into account to determine their prognosis or treatment decision. In addition, some of the recent studies raised the question of age being a negative prognostic factor in lung cancer treatment outcome.

A literature review conducted by Pallis and Gridelli on lung cancer treatment demonstrated that as life expectancy and the incidence in old age is increasing, the patients and oncologists face an issue on deciding whether to give or not to give the treatment [14]. The review concluded that if the same treatment is given to older fit patients the prognosis is similar to treatment outcome for a younger patient [14]. However, it is important to consider that the information included in the review was obtained from retrospective studies, which are prone to selection bias.

The importance of age in lung cancer is not only associated with survival but also with the complications after surgery and other complications associated with co-morbidities [15].

3.2 Socioeconomic Status

The prognostic significance of such health influencing factor in survival of cancer patients
seems controversial. Some studies reported that patients from the least deprived areas are supposed to have better prognosis compared to the most deprived areas. This disparities in survival explained by inequalities in clinical care and presentation with advanced stage in the most deprived patients. The other argument is that no relationship between socioeconomic status and survival of cancer patients.

A retrospective study on 19702 incident cases of NSCLC patients presented with stage I described low socio-economic status as an independent poor prognostic factor after adjusting for surgery, race and marital status [16]. Another study was conducted on patients of 13 different cancers, including lung cancer, in Australia, who were diagnosed between 1992 and 2000 and followed until the end of 2001 [17]. This study showed significantly worse survival after adjustment for age, sex, and with and without adjustment for stage of disease in lung cancer patients from the most deprived areas (p<0.0001). The study concluded that the difference in survival in different deprivation categories might be because of the difference in access to health care. Potosky et al. [18] also reported considerable variations in the pattern of initial treatment of NSCLC in the United State.

Regarding some existing literature in this field from Scotland, Campbell et al. [19] reported poorer one year survival rate for most deprived lung cancer patients compared with the least deprived (21.2% vs. 24%, p<0.001). Their study in 2002 suggested that the poorer survival of patients from deprived areas is because they are more likely to present with advanced stage at diagnosis, and not due to differences in treatment rates [20].

By contrast, some studies described the association between socio-economic status and lung cancer prognosis as non-significant. A retrospective study by Hui et al. [25] found no significant difference in survival of patients from different deprivation categories after adjustment for stage of disease, utilisation of different treatment modalities and health care services. However, this study had some serious limitations. Although the study showed to be adjusted for disease stage and health care services, the group which was more affluent had an older population compared to the other group, and as mentioned earlier that, older age would be associated with poor prognosis. This might have influenced the analysis to produce non-significant results (p=0.08). In statistical terms the results might not be entirely non-significant as the ‘p’ value is not much greater than 0.05 and there is existence of 3.3% excess survival for affluent category. There might be an accumulative effect of life style factors, diet and education.

### 3.3 Co-morbidity

Often co-morbidity is negatively associated with length of survival after the treatment for lung cancer. A study on 1155 patients showed a significant association between co-morbidity and poor survival in both initial and advanced stages of lung cancer after adjustment analysis [22]. The results of this study significantly explained survival by both common and uncommon co-morbidities. Nineteen common co-morbidities explained 6.1% of survival, while thirteen uncommon co-morbidities explained 3.5% of the survival variation [22].

Some of the researchers described co-morbidity as an independent prognostic factor. An analysis conducted on data of 1255 lung cancer patients reported that co-morbidity was significantly associated with the hazard of death [hazard ratio 1.28, 95% CI 1.09-1.5, p value 0.003] [23]. However, recently questions have been raised regarding considering co-morbidity as an important prognostic factor for lung cancer treatment. Some of the researchers denied co-morbidity as an independent prognostic factor.

Another study [24] used both the indexes (Charlson Co-morbidity Index and simplified Co-morbidity Index) for measuring co-morbidity and obtained that neither of the co-morbidity indexes was significantly associated with survival after lung cancer treatment (p=0.47 and p=0.24 respectively). The study related the co-morbidity with under-treatment and advised consideration of co-morbidity in treatment design rather than a factor of exclusion for oncologic treatment. But the study itself described the limitation in terms of sample size (83 patients) and described the result’s inference as hypothesis-generating rather than conclusive.

From the above discussion it can be inferred that although there are doubts over considering co-morbidity as an independent prognostic factor, the importance of co-morbidity in lung cancer treatment prognosis cannot be declined. The influence of co-morbidity on prognosis might not be solely because of itself, but rather a
combination of other factors including age, disease stage, treatment type and design.

3.4 Performance Status

Performance status (PS) scoring system such as the Eastern Cooperative Oncology Group (ECOG) is widely used in oncology to estimate the patient’s ability to carry out daily activities [25]. The ECOG scale was designed by the World Health Organisation, and it runs from (0 to 4). Performance status information is a crucial prognostic factor of lung cancer survival, and it is useful to determine the appropriate therapeutic course. As an example, patients with (PS 2) are at higher risk of chemotherapy complication, and surgery is not recommended [26].

3.5 Disease Factors

Certain factors associated with disease are directly linked with prognosis. Discussion and understating of these factors is important in order to comment on treatment and prognosis of the disease. Some of the most important disease-related factors are tumour size, lymph node involvement and distant metastasis or disease staging. These factors are also the important determinant in disease staging. To understand cancer stage, it would be useful to start by discussing the role of tumour size in lung cancer staging and prognosis.

3.5.1 Tumour size

One of the most important factors in determining the prognosis for a lung cancer patient is the tumour size, especially in the early stages of the disease. A study by Port et al. [27] conducted analysis on 244 patients and showed that patients with lung tumour size of less than 2 cm had a higher 5-year survival rate than patients with tumour size of 2 to 3 cm. The study concluded that, in order to accurately assess and treat the disease there may be a need of further sub-staging apart from the current lung cancer staging guidelines, which categorise lung tumour as being less than, equal to, or more than the baseline value of 3 cm.

Similarly, another study by Cangir et al. [28] involving 550 patients, described tumour size as an important prognostic factor. The study presented that the 5 years survival with tumours larger than 5 cm was 31.4%, while for the tumours 3-5 cm is 45.9% which is significantly higher in the latter (P = 0.005). While other studies reported that tumour size is an important survival factor in NSCLC [29,30], the association between tumour size and stage distribution is still controversial [31].

Tumour size might be linked with the spread of cancer i.e. metastasis that ultimately decides the survival rather than tumour size. However, these views were not supported by researches held to explain the association between tumour size and metastasis. A retrospective study by Heyneman et al. [32] focused on patients with tumour size measuring from less than one centimetre to three centimetres. The researchers concluded from their analysed data that the advanced stage of the lung cancer is not determined by the size of the tumour as data showed that even the smaller tumours could represent an advanced stage of this cancer. They explained that their study suggests that the size of tumours less than or equal to three centimetres plays only a limited role in the metastasis of lung cancer. Regardless of the size of lesion at detection, patients with a primary lesion which is three centimetres or smaller in size will have an approximately 80-85% probability of having stage I lung cancer, and an approximately 10% chance of having stage IV lung cancer [32].

The above discussion underlines the importance of tumour size as a prognostic factor and questions the view that tumour size only decides the metastasis and ultimately the prognosis.

3.5.2 Metastasis and/or tumour stage

The stage of the tumour has a major impact on lung cancer prognosis. Cancer staging is the process of determining tumour size, growth rate, possible metastasis, lymph node involvement, treatment options and prognosis. NSCLC stages range from stage I, in which the cancer has not metastatised, to stage IV, in which the cancer has spread [32].

A number of studies have concluded that there is strong association between metastasis and survival of the patient after lung cancer treatment. They presented an inverse relation between stage and lung cancer prognosis i.e. more advanced stage is associated with lower survival rate [33,34].

A retrospective study by Agarwal et al. (2010) estimated survival after surgical treatment and control for age, sex and other factors for NSCLC patients with stage IA, IB, and IIB as 2648 days, 2085 days and 1405 days, respectively.
3.6 Treatment Modalities

Increasing researches have shown a strong association between active treatment and survival improvement of lung cancer, especially in NSCLC. It was estimated that 50% of lung cancer patients are treated with palliative therapy, because they are either presenting with metastatic disease or are medically unfit for active treatments.

Surgical treatment was found to be beneficial for 30% of tumours. Radiotherapy alone or combined with chemotherapy shows a better response in the further 20% of local advanced tumours [35]. A study reported the overall 5-year and 10-year relative survival rates for active treated patients as 14% and 8%, respectively. Whereas for patients who received no cancer directed treatments, these estimations were 5% and 2% respectively [36].

Similarly, higher active treatments rates in NSCLC patients were associated with better one year survival rates (23%) compared with (19%) for those received lower treatment rates [37].

A systematic review and meta-analysis of sixteen randomised controlled trials has provided strong evidence on the role of chemotherapy in improving overall survival in all patients with advanced NSCLC, this in addition to supportive care (NSCLC Meta-Analysis Collaborative Group, 2008). A prospective study on lung cancer patients from the South of Scotland reported median survival of patients after treatment with radiotherapy and chemotherapy as 207 days and 251 days respectively [38].

3.7 Health Care Factors

There is availability of different diagnostic and treatment options with advancement in research in the area. These advancements have improved survival time of the lung cancer patients, especially one-year survival. However, the concern stands with the access and timely availability of these options to the population at the risk of lung cancer and/or lung cancer patients. Certain health care factors are quite important determinants of survival of a lung cancer patient. These factors include access to health care, waiting time for treatment after diagnosis and after- treatment needs.

3.7.1 Access to health care

There have been some researches indicated that the association between socio-economic status and survival could be described by access to health care, which ultimately affects the survival in lung cancer patients [39]. However, access to health care might not be linked with the socio-economic status as in countries like the UK, where the treatment is offered even for the population of low socio-economic groups. Campbell et al. (2002) found that socioeconomic status is unlikely to lead to any delay in treatment after the referral point. A recently conducted research in Korea found a non-significant association between social class and access to health care in different deprivation categories [40].

However, there is a need for research in this area to identify the factors which describe the access to health care as being a prognostic factor in survival from lung cancer.

3.7.2 Waiting time for treatment

Recently, researchers have started focussing on the relationship of waiting time for treatment and survival. The reason behind the research was to ascertain whether delay in delivery or obtaining treatment, which might lead to worsening the condition of the disease, affects the survival after the treatment. Various researchers have come up with contrasting views. One of the researchers described the association between increased waiting time and re-occurrence and ultimately poor survival but the results were not similar for different types of cancer [41]. However, they highlighted the importance of waiting time in disease prognosis.

3.7.3 After treatment needs

It is important to provide support services for improving the quality of life or prognosis of cancer patients after treatment. Although most of the patients adjust to the morbidity after treatment, some feel psychological distress and sometimes feel anxiety and depression. Hence there is interaction between the clinical side and support service side of the patient. There is a need to address the issue of after- treatment needs as we concentrate on the treatment of the disease. There might be a need for interdisciplinary action to meet the demands of such situations. However, at present, the majority of the patients do not obtain support services
after treatment but these services are quite important to deliver, especially to females [42].

4. CONCLUSION

There are a wide range of prognostic factors which determine survival duration of lung cancer patients. Lung cancer survival is not dependent on a single factor of these prognostics, but is affected by the interaction between them. Among the most important factors are patient demographics, disease factors, and health care related factors.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

ACKNOWLEDGEMENT

I would like to express my sincere gratitude to Dr. Helen Marlborough, a senior assistant librarian at university of Glasgow for her unlimited support during the electronic literature searches, and extend my thanks to the editor and reviewers for their valuable comments on previous version of this manuscript.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES


34. Nykamp V. Surgical treatment of non-small cell lung cancer. [Review] [9 refs]. South


© 2019 Houssein; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here: https://sdiarticle4.com/review-history/52676